425: InMed Pharmaceuticals Amends Merger Agreement with Mentari Therapeutics

InMed Pharmaceuticals and Mentari Therapeutics have amended their merger agreement, clarifying transaction sequencing, pre-closing financing impacts, and tax treatment, while also filing a Form S-4 registration statement.

Summary

• InMed Pharmaceuticals Inc. and Mentari Therapeutics, Inc. have entered into an amendment to their existing merger agreement, originally dated May 19, 2026.
• The amendment clarifies the order of events for the merger, including InMed changing its name to Mentari Therapeutics, Inc. prior to closing and redomesticating from British Columbia to Nevada.
• It also addresses the impact of potential additional private placement financing (Company PIPE Amendment) on the exchange ratio and clarifies the intended tax treatment of the merger as a reorganization under Section 368(a) of the Internal Revenue Code.
• A registration statement on Form S-4, containing a preliminary joint proxy statement/prospectus and management information circular, was filed with the SEC on July 2, 2026, to facilitate the proposed transaction.
• The merger is expected to close in the fourth quarter of 2026, subject to shareholder approvals, effectiveness of the S-4, and other customary closing conditions.

Sentiment

Score: 6

Explanation: StockSavvy.ai views this as a neutral to slightly positive development, as the amendment clarifies key aspects of the merger, reducing uncertainty, but also introduces potential complexities regarding financing and exchange ratios.

Positives

• Clarification of merger transaction sequencing and tax treatment provides greater certainty for the parties involved.
• The amendment facilitates potential additional private placement financing, which could strengthen the combined company's financial position.
• The filing of the Form S-4 is a significant step towards the completion of the merger, indicating progress in the regulatory process.
• The merger is expected to close in Q4 2026, providing a timeline for the combined entity's operations.

Negatives

• The merger is still subject to various closing conditions, including shareholder approvals and regulatory effectiveness, which could lead to delays or termination.
• The effectiveness of the Form S-4 is pending SEC review, and any changes to its content due to the amendment could impact the timeline.
• The potential for additional private placement financing introduces complexity and could affect the exchange ratio, impacting existing shareholders.

Risks

• Failure to obtain shareholder approval from InMed and Mentari.
• Failure to satisfy other closing conditions or obtain required regulatory approvals.
• Delays in obtaining or adverse outcomes related to regulatory approvals.
• The possibility of the merger agreement being terminated.
• InMed's ability to maintain its Nasdaq listing.
• Unexpected costs, charges, or expenses resulting from the proposed transaction.
• The effect of the announcement or pendency of the transaction on existing and potential business relationships and operating results.
• Risks associated with Mentari's drug candidates, including the outcome of preclinical studies and clinical trials, and regulatory approval processes.
• Competition in the migraine treatment market.
• The combined company's reliance on third parties and protection of intellectual property.
• The combined company's need for substantial additional funding.

Future Outlook

The merger is anticipated to close in the fourth quarter of 2026, subject to shareholder approvals, the effectiveness of the Form S-4, and other customary closing conditions. The combined company is expected to be listed on Nasdaq. Forward-looking statements indicate expectations regarding the structure, timing, and completion of the merger, the combined company's operations, development, and commercial potential.

Management Comments

• The Parent Board has determined that the Contemplated Transactions (including as amended) are fair to, advisable and in the best interests of Parent and its shareholders, and has recommended that shareholders vote to approve the Merger Agreement.
• The Company Board has determined that the Contemplated Transactions (including as amended) are fair to, advisable and in the best interests of the Company and its stockholders, and has recommended that stockholders vote to adopt the Merger Agreement.
• InMed and Mentari are urging investors and shareholders to read the Form S-4, proxy statement/prospectus, and management information circular carefully when available, as they will contain important information about the transaction.

Industry Context

StockSavvy.ai notes that this amendment to the merger agreement between InMed Pharmaceuticals and Mentari Therapeutics reflects common adjustments in biotech M&A, particularly concerning financing structures and tax implications to optimize deal terms and regulatory compliance. The focus on migraine therapies by Mentari aligns with a growing area of pharmaceutical development.

Corporate Governance

Stakeholder Impact

• Shareholders of InMed: May experience changes in ownership structure and potential dilution depending on the outcome of pre-closing financing. The redomestication and name change will also affect their investment.
• Shareholders of Mentari: Will receive InMed shares as part of the merger, with the exchange ratio potentially influenced by pre-closing financing.
• Employees: May face changes in roles, responsibilities, and organizational structure post-merger.
• Creditors: The financial health and structure of the combined entity will impact creditors.

Next Steps

• SEC effectiveness of the Form S-4 registration statement.
• Holding of a special meeting for InMed shareholders to approve the transaction.
• Obtaining approval from Mentari stockholders.
• Satisfaction of other customary closing conditions.
• Completion of the merger, expected in Q4 2026.

Key Dates

Recommendation

The amendment clarifies the merger terms, which is a positive step, but the transaction is still subject to significant conditions and regulatory approvals. The potential for pre-closing financing adds complexity. Investors should await further developments, including the effectiveness of the S-4 and shareholder votes, before making a definitive decision.

Keywords

InMed Pharmaceuticals, Mentari Therapeutics, Merger Agreement, Amendment, Form S-4, SEC Filing, Biotechnology, Merger, Corporate Reorganization, Tax Treatment, Private Placement, Nasdaq